ELTP · Elite Pharmaceuticals Inc /Nv/
$0.38
-0.01 (-1.32%)
At close · Jul 28
Market Cap
$403.95M
Shares
1.08B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$148.87M
+77.1%
FY2026
Net Income
$44.87M
+1140%
FY2026
Gross Margin
50.4%
+2.7pp
FY2026
Operating Margin
32.99%
+9.7pp
FY2026
Diluted EPS
$0.03
FY2026
Operating Cash Flow
$23.75M
+218.5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $148.87M | $84.04M | $56.63M | $34.16M | $32.26M | $25.38M | $17.99M | $7.57M | $7.46M | $9.64M | $12.5M | $5.02M | $4.6M | $3.4M | $2.42M | $4.27M | |
| $73.85M | $43.96M | $30.27M | $17.56M | $17.47M | $13.51M | $10.02M | $4.7M | $3.51M | $5.9M | $4.48M | $3.01M | $3.24M | $2.32M | $1.01M | $2.68M | |
| $75.02M | $40.09M | $26.36M | $16.59M | $14.8M | $11.87M | $7.98M | $2.87M | $3.95M | $3.74M | $8.01M | $2M | $1.37M | $1.09M | $1.41M | $1.59M | |
| 50.4% | 47.7% | 46.55% | 48.58% | 45.86% | 46.76% | 44.34% | 37.89% | 52.93% | 38.8% | 64.12% | 39.91% | 29.67% | 31.98% | 58.18% | 37.29% | |
| $5.74M | $7.96M | $6.88M | $6.2M | $4.05M | $5.11M | $5.53M | $7.6M | $9.62M | $8.3M | $12.43M | $14.73M | $3.96M | $975.25K | $1.74M | $1.39M | |
| $17.6M | $9M | $7.15M | $5.12M | $4.46M | $3.32M | $3.35M | $3.08M | $2.33M | $2.08M | $2.9M | $2.9M | $2.11M | $1.51M | $1.41M | $876.01K | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | — | |
| $1.07M | $1.23M | $1.32M | $1.28M | $1.21M | $1.31M | $1.32M | $1.26M | $996.41K | $714.53K | $666.46K | $581.86K | $453.75K | $423.34K | $484.15K | $483.47K | |
| $25.91M | $20.49M | $15.57M | $12.92M | $9.72M | $9.76M | $10.26M | $12.03M | $13M | $11.1M | $16.33M | $18.51M | $6.65M | $2.65M | $3.38M | $2.48M | |
| $49.11M | $19.6M | $10.79M | $3.68M | $5.07M | $2.1M | -$2.29M | -$9.16M | -$9.05M | -$7.36M | -$8.32M | -$16.51M | -$5.28M | -$1.56M | -$1.97M | -$885.76K | |
| 32.99% | 23.32% | 19.05% | 10.76% | 15.72% | 8.29% | -12.7% | -121.01% | -121.35% | -76.32% | -66.54% | -329.14% | -114.83% | -45.93% | -81.11% | -20.76% | |
| $50.18M | $20.83M | $12.11M | $4.95M | $6.28M | $3.42M | -$965.61K | -$7.9M | -$8.05M | -$6.64M | -$7.65M | -$15.93M | -$4.83M | -$1.14M | -$1.48M | -$402.29K | |
| — | — | $588.62K | $1.11M | $191.82K | $259.6K | $355.87K | $369.17K | $335.5K | $238.22K | $280.67K | $287.23K | $859.33K | $253.75K | $229.59K | $231.75K | |
| $207.86K | $20.94K | $20.92K | $7453 | $126 | $514 | $11.98K | $21.46K | $17.51K | $12.62K | $0 | $0 | $0 | — | — | — | |
| $7.7M | -$19.65M | -$10.33M | $309.87K | $1.23M | $2.04M | $47.06K | -$796.64K | $4.33M | $9.3M | $7.11M | $21.72M | -$36.27M | $2.7M | -$13.58M | -$13M | |
| $56.81M | -$52.14K | $463.09K | $3.99M | $6.3M | $4.14M | -$2.24M | -$9.96M | -$4.72M | $1.94M | -$1.2M | $5.22M | -$41.55M | $1.13M | -$15.54M | -$13.88M | |
| $11.94M | $4.26M | -$19.65M | $424.03K | -$1.74M | — | — | -$676.02K | -$1.05M | -$1.87M | -$520.45K | -$3249 | -$292.61K | — | — | — | |
| $44.87M | -$4.31M | $20.11M | $3.56M | $8.9M | $5.09M | -$2.24M | -$9.28M | -$3.67M | $3.81M | -$683.01K | $5.22M | -$41.26M | $1.49M | -$15.06M | -$13.58M | |
| 30.14% | -5.13% | 35.51% | 10.43% | 27.58% | 20.05% | -12.45% | -122.6% | -49.25% | 39.54% | -5.46% | 104.09% | -896.71% | 43.72% | -621.19% | -318.38% | |
| $44.87M | -$4.31M | $20.11M | $3.56M | $8.9M | $5.09M | -$2.24M | -$9.28M | -$3.67M | $24.53M | -$9.97M | $28.93M | -$96.58M | $1.49M | -$15.17M | — | |
| USD/shares | $0.04 | $0.00 | $0.02 | $0.00 | $0.01 | $0.01 | $0.00 | -$0.01 | $0.00 | $0.03 | -$0.01 | $0.05 | -$0.21 | $0.00 | -$0.06 | — |
| USD/shares | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.02 | -$0.21 | $0.00 | -$0.06 | — |
| shares | 1.07B | 1.07B | 1.02B | 1.01B | 1.01B | 943M | 832.33M | 814.17M | 796.07M | 838.67M | 673.91M | 591.21M | 463.02M | 349.08M | 259.16M | — |
| shares | 1.14B | 1.07B | 1.02B | 1.01B | 1.01B | 943M | 993.26M | 816.31M | 798.17M | 844.51M | 673.91M | 757.58M | 463.02M | 526.88M | 259.16M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.00×
EV/EBIT
—
Peer median 34.20×
P/E (TTM)
12.50×
Peer median 15.54×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Abbreviated New Drug Applications | $84,043,929 | $56,625,128 | $34,155,114 | $32,262,117 | $25,214,582 |
| New Drug Applications | — | — | — | — | $166,167 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Manufacturing | $147,810,122 | $81,986,079 | $54,120,731 | $29,187,573 |
| Scheduled Products Manufacturing Fees | $141,465,975 | $74,756,506 | — | — |
| Indirect Sales to Wholesalers | $82,536,359 | $33,977,093 | — | — |
| Direct Sales to Wholesalers | $65,273,763 | $48,008,986 | — | — |
| Unscheduled Products Manufacturing Fees | $6,344,147 | $7,229,573 | — | — |
| Licensing | $1,059,997 | $2,057,850 | $2,504,397 | $4,967,541 |
| Unscheduled Products Licensing Fees | $594,486 | $1,809,061 | — | — |
| Scheduled Products Licensing Fees | $465,511 | $248,789 | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Abbreviated New Drug Applications | $32,121,818 | $19,473,752 | $10,393,857 | $10,744,005 | $6,512,632 | $1,869,491 |
| Business Segment | $32,121,818 | $19,473,752 | $10,393,857 | $10,744,005 | $6,655,444 | $2,023,275 |
| New Drug Applications | — | — | — | — | $142,812 | $153,784 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Abbreviated New Drug Applications | 38.2% | 34.4% | 30.4% | 33.3% | 25.8% |
| New Drug Applications | — | — | — | — | 85.9% |